Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant HypertensionNovelty and Significance [Clinical Study: Resistant Hypertension Optimal Treatment Trial (ReHOT)]

The aim of this study is to compare spironolactone versus clonidine as the fourth drug in patients with resistant hypertension in a multicenter, randomized trial. Medical therapy adherence was checked by pill counting. Patients with resistant hypertension (no office and ambulatory blood pressure [BP] monitoring control, despite treatment with 3 drugs, including a diuretic, for 12 weeks) were randomized to an additional 12-week treatment with spironolactone (12.5–50 mg QD) or clonidine (0.1–0.3 mg BID). The primary end point was BP control during office (

Source: Hypertension - March 7, 2018 Category: Cardiology Authors: Eduardo M. Krieger, Luciano F. Drager, Dante M.A. Giorgi, Alexandre C. Pereira, Jose Augusto Soares Barreto–Filho, Armando R. Nogueira, Jose Geraldo Mill, Paulo A. Lotufo, Celso Amodeo, Marcelo C. Batista, Luiz C. Bodanese, Antonio C.C. Carvalho, Ir Tags: Clinical Studies, Hypertension Original Articles Source Type: research